Mr. Walbert has been a member of our board of directors since March 2014 and has served as our chair since June 2015. Mr. Walbert has been the president and chief executive officer of Horizon Pharma since June 2008 and has been the chairman of the Horizon board since 2010. Previously, he served as president, chief executive officer, and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations, at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which had almost $20 billion in 2018 sales and divisional vice president, global cardiovascular strategy, at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America, and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc., and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. In addition to the Zyla board of directors, Mr. Walbert serves on the Biotechnology Innovation Organization (BIO), Illinois Biotechnology Innovation Organization (iBIO), World Business Chicago and Greater Chicago Arthritis Foundation boards. He is a member of the Illinois Innovation Council, the National Organization of Rare Disease (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College.
Mr. Todd Holmes joined our board of directors on January 31, 2019. Since joining in 2018, he has been a principal at CRG where he leads investment sourcing, diligence and execution in various sectors including specialty pharma, medical technology and healthcare services. Mr. Holmes has 15 years of investing, company building and transaction experience across private and public sectors. Prior to joining CRG, Mr. Holmes was an investor and founding member of Gurnet Point Capital where he led investments and acquisitions across multiple stages and sectors within healthcare. Previously, Mr. Holmes was a member of Third Rock Ventures where he held investment and operational roles and was part of the founding team at Ember Therapeutics. Earlier in his career, he was an investor at BVF Partners, a biotechnology-focused hedge fund, and a member of the commercial lending practice at Silicon Valley Bank. Mr. Holmes received a bachelor’s degree in Economics from Colgate University and an MBA from the Wharton School at the University of Pennsylvania.
Mr. Joe McInnis has been a member of our board of directors since January 31, 2019. He has almost two decades of experience in finance. Since 2015, Mr. McInnis has been a principal at Murrin Construction, a provider of aggregates and dimension stone. Prior to joining Murrin, he was a managing director and investment analyst at Greywolf Capital which he joined in 2004. Before Greywolf, Mr. McInnis worked for three years as an investment analyst in the special situations investing group at Goldman Sachs & Co. In addition to being on our board, he is a director on the Aspire Oil & Gas and Washington Mutual board of directors. He received his bachelor’s at the University of British Columbia.
Mr. Pauls has been a member of our board of directors since January 31, 2019. He has more than 20 years of leadership experience in the pharmaceutical industry, with an emphasis on specialty pharma and orphan/rare diseases. Mr. Pauls brings extensive general management and commercial leadership experience, and has served as President, CEO and director of Strongbridge Biopharma plc since August of 2014. Strongbridge Biopharma, an Irish-domiciled company with U.S. headquarters in Trevose, Pennsylvania, is a NASDAQ-listed biopharma company focused on developing and commercializing therapies for rare diseases. Before joining Strongbridge, Mr. Pauls was the chief commercial officer at Insmed, a NASDAQ-listed biopharmaceutical company. Prior to that, he served as senior vice president, head of global commercial operations at Shire Pharmaceuticals and held senior positions at Bristol-Myers Squibb in brand management and payer marketing, and at Johnson & Johnson in various U.S. and global commercial roles. In addition to Zyla and Strongbridge, Mr. Pauls serves on the board of directors of Savara Pharmaceuticals The Pennington School in Pennington, New Jersey. He received a bachelor’s degree and an MBA from Central Michigan University and earned his JD from Michigan State University College of Law.
Gary Phillips, M.D.
Dr. Phillips has been a member of the Zyla board of directors since June 2019. He is the president and chief executive officer of OrphoMed, Inc., a biopharma company focused on gastrointestinal diseases and pain. Prior to OrphoMed, Dr. Phillips was executive vice president and chief strategy officer at Mallinckrodt Pharmaceuticals for five years. Previously, he was head of Global Health & Healthcare Industries at the World Economic Forum. Earlier, he was president of Reckitt Benckiser Pharmaceuticals North America (now Indivior) and held dual roles as president, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb. Additionally, Dr. Phillips served in executive roles at Merck Serono, Novartis and Wyeth. Dr. Phillips is a member of the board of directors at Aldeyra Therapeutics. He earned his bachelor’s degree in Biochemistry with Summa Cum Laude and Phi Beta Kappa distinctions, an MBA and a medical degree with Alpha Omega Alpha distinction all from the University of Pennsylvania. Dr. Phillips practiced as a general medicine clinician/officer in the U.S. Navy and maintains an active medical license.
Andrea Heslin Smiley
Ms. Smiley has served as a member of our board of directors since April 2017. She has approximately three decades of commercialization and general management experience in the biopharmaceutical industry in both public and private companies. Since 2011, Ms. Smiley has served as president and CEO at VMS BioMarketing, a leading provider of patient and healthcare provider support. Within her first year as CEO of VMS BioMarketing, she spun-off commoditized business units and focused the company solely on impacting patient adherence and outcomes. During her tenure as CEO, she has established VMS as the leading provider and growth leader of clinical nurse educator patient support solutions. Ms. Smiley provides strategic consulting to VMS’ biopharma clients on pre- and post-commercialization strategies across a broad range of therapeutic areas including immunology, oncology, endocrinology, neuroscience and rare diseases. Prior to joining VMS BioMarketing in 2008, Ms. Smiley spent 18 years at Eli Lilly and Company in various positions of increasing responsibility in finance, business development, corporate affairs, brand management and business unit leadership roles. Among other programs, she was the marketing leader for the launch of Humalog® Mix75/25™, she led sales and marketing for Humatrope®, she was responsible for the development and launch of Forteo® and she was the business unit leader of Lilly’s women’s health business. Earlier in her career, Ms. Smiley worked as a management consultant for Putnam Associates, where she led consulting teams and advised brands in the biotechnology, pharmaceutical and managed healthcare ﬁelds on product launches and access strategies. She is a regular speaker and panel member on patient adherence, patient services and women’s leadership topics at biopharma industry conferences. Ms. Smiley serves on the board of numerous nonprofit organizations including: Indiana Alzheimer’s Association, Summer Stock, Indiana Salvation Army and the Lung Force Women’s Cabinet. She received a gubernatorial appointment to the Indiana Commission for Women. In addition to Zyla, she is on the board of AppianRx, a privately held, technology-based specialty pharmacy and patient support solutions company. Ms. Smiley earned her BA in economics from DePauw University where she was an Honors Management Fellow.
Mr. Smith joined Zyla as president, chief executive officer (CEO) and a member of the board of directors in October 2019. With more than 25 years of pharmaceutical, medical device and biotechnology leadership, he has a long track record of building companies and achieving commercial and business development excellence while maintaining a focus on patient access to differentiated products. Before joining Zyla, from 2017 through February 2019, Mr. Smith, served as CEO and a director of Iroko Pharmaceuticals Inc., a privately-owned pharmaceutical company, from which the Company purchased five products in early 2019. During the period October 2014 through June 2015, Mr. Smith served as the chief commercial officer of Ophthotech Corporation, a biopharmaceutical company focused on developing novel therapeutics to treat ophthalmic diseases. In addition, he has held a variety of senior commercial and marketing roles at organizations including Horizon Therapeutics plc, a public biopharmaceutical company focused on rare and rheumatic diseases, and Abbott, a public healthcare products company. Mr. Smith serves as a director for BVI, a TPG Ophthalmology company and for Vault Nano, a UCLA Biotech in Immuno-Oncology and Virology. Mr. Smith received his bachelor’s degree from Norwich University.